An interventional study of Brief Cognitive Behavioral Therapy (BCBT) and Treatment as usual (TAU) in Suicidal Ideation, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Ohio State University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Suicidal Ideation by Ohio State University — 5 open to participants now, 5 under way, none of them phase 3. Suicidal Ideation · Ohio State University.
Among the 10 studies in Suicidal Ideation by Ohio State University, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 10 with no phase, and was the 7th registered.
570 studies on the registry are indexed under Suicidal Ideation; 204 are open to participants now.
Browse Suicidal Ideation studies →5 of the 10 studies in Suicidal Ideation by Ohio State University are open now, in 1 country. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 135 Suicidal Ideation studies recruiting now, 52 (39%) set no upper age limit and 79 (59%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 1,200 is above the median of 80 across 470 interventional studies indexed under Suicidal Ideation.
Median enrollment 99 across the 10 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
3 of the studies in Suicidal Ideation by Ohio State University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06285708Ohio State UniversityEnhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD | 2026-12 |
| NCT05722197Ohio State UniversityAssessment of Emotion Regulation Strategies Used When Suicidal | 2027-01-23 |
| NCT07238192Ohio State UniversityAugmenting Massed Cognitive Processing Therapy (CPT) to Prevent Suicide Risk Among Patients With PTSD | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Suicidal Ideation by Ohio State University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interventional study is to develop and test a treatment prognosis calculator to identify which service members with suicidal ideation or behavior are likely to respond well to the current standard of care treatment and which should instead receive Brief Cognitive Behavioral Therapy (BCBT) as a first-line treatment.
The main aims of the study are:
Participants will receive mental health treatment as it is typically administered by their mental healthcare treatment team. Members of their mental healthcare treatment team may receive intensive training in BCBT. After their provider has received this training, they may use this treatment as part of standard of care treatment. The timing of this training will be determined randomly. Participants will complete self-report assessments at the beginning of the study (baseline) as well as 3, 6, 9 and 12 months after their participant begins. These assessments will include questions about feelings, thoughts, moods, impulses, substance use, and behavior.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(1) participants with a psychiatric or medical condition that prevents them from providing or from participating in the treatments (e.g., psychosis, mania, acute intoxication).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAU may include (1) routine suicide risk screening and assessment; (2) safety planning with means restriction; and (3) the Collaborative Assessment and Management of Suicidality (CAMS), an evidence-based approach to managing and treating suicidal patients.
Behavioral: Treatment as usual (TAU)
BCBT consists of 12 outpatient individual psychotherapy sessions scheduled weekly or biweekly. The first session is 90 minutes and subsequent sessions are 60 minutes. BCBT is divided into three phases. In phase 1 (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase 2 (5 sessions), the therapist teaches cognitive restructuring skills to build cognitive flexibility. In phase 3 (2 sessions), a relapse prevention task is conducted, and participants must demonstrate the ability to successfully complete this task in order to terminate the treatment. Additional sessions are conducted until participants demonstrate the ability to successfully complete this task.
Behavioral: Brief Cognitive Behavioral Therapy (BCBT)
BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
Behavioral health treatment as it is typically provided at the treatment site.
Suicidal Ideation
Assess severity of suicidal ideation at 6 months with the Scale for Suicide Ideation (SSI)
Time frame: 6 Months
Suicide Attempts
Suicide attempts will be assessed with the Self-Injurious Thoughts and Behaviors Interview-Revised (SITBI-R)
Time frame: 12 Months
Depression
Depression will be assessed with the PROMIS-Depression Computer Adaptive Test (CAT)
Time frame: 12 Months
Hopelessness
Hopelessness will be assessed with the abbreviated Beck Hopelessness Scale (BHS)
Time frame: 12 Months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
Of 282 non-industry interventional studies with no phase under Suicidal Ideation, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 24 months is below that.
Counting every sponsor, half of 291 studies reached it within 30 months; a quarter within 13 and three quarters within 54.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Oct 2023 → Oct 2026, primary completion Aug 2026 → Oct 2028 and completion Aug 2027 → Aug 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.